Skip to content

Initial procedure of mini ThoracOthomic ablation of Persistent Atrial Fibrillation versus percutaneous catheter approach

A controlled trial to determine whether the minimally invasive surgical ablation of persistent atrial fibrillation performed as the initial procedure is more effective than percutaneous catheter approach in achieving normal sinus rhythm after one year

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN08035058
Enrollment
150
Registered
2013-06-20
Start date
2013-09-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Persistent Atrial Fibrillation as defined by the 2012 Focused Updated of the ESC guidelines for the management of AF. Europ Heart J (2012)33:2719 Circulatory System Atrial fibrillation and flutter

Interventions

Patients will be randomized to the percutaneous catheter (100 patients) or to the Surgical (50 patients) ablation as first procedure. After 3 months they will be re-evaluated according to the same gu

Sponsors

The Catholic University of the Sacred Heart (Università Cattolica S. Cuore Roma) (Italy)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The inclusion and exclusion criteria, definitions and treatment protocols are those reported by the 2012 HRS/EHRA/ECAS expert consensus statement on cathter and surgical ablation of atrial fibrillation. J Interv Card Elecrophysiol (2012);33:171 Inclusion criteria 1. Patients who are 18 years of age or older 2. Patients with persistent AF, which is defined as a sustained episode lasting more than 7 days in the last 12 months 3. Patients with symptomatic AF that is refractory to at least one antiarrhythmic medication. Symptomatic patients are those who have been aware of their AF at anytime within the last 5 years before enrollment. Symptoms may include, but are not restricted to, palpitations, shortness of breath, chest pain, fatigue, left ventricular dysfunction, or other symptoms, or any combination of the above. 4. At least one episode of persistent AF must have been documented by ECG, Holter, loop recorder, telemetry, transtelephonic monitor, or implantable device within last 2 years of enrollment in this investigation. 5. Patients must be able and willing to provide written informed consent to participate in this investigation 6. Patients must be willing and able to comply with all periablation and follow-up requirements

Exclusion criteria

Exclusion criteria: 1. Patients with paroxysmal AF, whic is defined as a sustained episode lasting >7 days 2. Patients with long-standing persistent AF, which is defined as a sustained episode lasting >1 year 3. Patients for whom cardioversion or sinus rhythm will never be attempted/pursued 4. Patients with AF secondary to a reversible cause 5. Patients with contraindications to systemic anticoagulation 6. Patients with left atrial size =55 mm (2-dimensional echocardiography, parasternal long-axis view) 7. Patients with LA thrombi as demonstrated by TEE

Design outcomes

Primary

MeasureTime frame
1. Freedom from AF at 12 months as detected by a 12 leads ECG and a 24 H Holter examination after a 3, 6 and 9 months follow-up 2. A repeated procedure to achieve a 12 months freedom from AF

Secondary

MeasureTime frame
Any documented atrial arrhythmia like atrial fibrillation (AF) or a trial flutter (AFL) or atrial tachycardia (AT)

Countries

Italy

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 8, 2026